M. Amin Khan, PhD, has spent over 30 years working in pharmaceutical and vaccine R&D across large Pharma and small Biotech and has played critical roles in integrated R&D programs demonstrating rapid clinical translation and navigating the late-stage development of vaccine products.  Currently, he is an advisor to vaccine and biologics companies operating in the Americas, Europe, and Africa.  Most recently, he was the Executive Vice President and Head of R&D at Icosavax, Inc. (acquired by AstraZeneca, February 2024).

Amin has held senior scientific and executive leadership roles at Eli Lilly (Distinguished Research Fellow), Novartis Vaccines (V.P. Technical R&D), and GlaxoSmithKline (Global Head, Vaccines Technical R&D & R&D Acceleration Team Leader).   He has guided scientific and technical teams in developing novel vaccines for infectious diseases, including targets for RSV, influenza, meningitis, group B Streptococcus, S. aureus, COPD, CMV, herpes zoster, and SARS-CoV-22, and has contributed to the licensure of four vaccines. These programs utilized a broad range of enabling technologies, including recombinant proteins, viral vectors, and nucleic acids. Amin holds a PhD in Pharmaceutical Sciences from the University of Nottingham, UK.